” As part of Operation Warp Speed, we are broadening U.S.-based production of the products that are necessary in the advancement and manufacturing of COVID-19 vaccines,” HHS Secretary Alex Azar stated in a press release. “By expanding capacity now, not just do we help deliver these items as quickly as possible, however we likewise return manufacturing to America, improving the economy and preparing us for future crises.”.
The contract needs Cytiva to increase its production capacity for vaccine elements at its Massachusetts facilities and begin manufacturing them at its Utah facilities. HHS has actually informed the business this must be completed in less than a year, as it currently only produces these products in Massachusetts.
More articles on drug store: Walgreens 4th-quarter sales at retail pharmacies up 3.6% Halting of Eli Lilly coronavirus drug trial more worrying than other 2 trial delays, professionals state$ 200 Medicare drug cards wont show up prior to Election Day.
Katie Adams –
Thursday, October 15th, 2020
HHS stated it will provide $31 million to Massachusetts pharmaceutical manufacturer Cytiva to scale up its production of materials needed to produce COVID-19 vaccines, the department announced Oct. 13.
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by click on this link.
The financing will enable Cytiva to broaden its capacity to make products such as dry and liquid powder cell culture media, cell culture buffers, bioreactors and mixer bags.